Neurocrine Biosciences (NBIX) Free Cash Flow (2010 - 2026)

Neurocrine Biosciences has reported Free Cash Flow for 17 years, with the latest figure at $136.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 152.68% year-over-year to $136.7 million; the trailing twelve-month figure through Mar 2026 stood at $831.3 million (up 72.43% YoY), and the FY2025 full-year result was $748.7 million, up 34.37% from the prior year.
• Free Cash Flow for Q1 2026 stood at $136.7 million, down from $355.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $355.0 million in Q4 2025, with the low at -$125.8 million in Q1 2023.
• Historically, Free Cash Flow has averaged $125.1 million across 5 years, with a median of $129.2 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 657.14% — and 2023, when it sank 161.54%.
• Neurocrine Biosciences' Free Cash Flow stood at $127.2 million in 2022, then fell by 24.45% to $96.1 million in 2023, then surged by 144.75% to $235.2 million in 2024, then surged by 50.94% to $355.0 million in 2025, then tumbled by 61.49% to $136.7 million in 2026.
• The last three Free Cash Flow figures came in at $136.7 million (Q1 2026), $355.0 million (Q4 2025), and $250.1 million (Q3 2025), per Business Quant data.